News

Alterity Therapeutics Shares Advances in MRI Technology for MSA

Alterity Therapeutics Shares Advances in MRI Technology for MSA

Alterity Therapeutics Releases New Findings on MRI Endpoint

- Innovative publication in Annals of Clinical and Translational Neurology showcases MSA Atrophy Index for Multiple System Atrophy progression tracking -

MELBOURNE, Australia and SAN FRANCISCO - Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a pioneering biotechnology firm focused on neurodegenerative diseases, recently revealed transformative findings regarding their Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History Study. This significant research has been documented in a peer-reviewed edition of Annals of Clinical and Translational Neurology.

The publication, titled "The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy," elaborates on the deployment of cutting-edge deep learning methods, which leverage artificial intelligence to delineate the neuroanatomy of critical regions within the brain. This innovative approach has yielded a groundbreaking brain atrophy measure crucial for tracking disease progression in MSA patients over the course of a year, correlating these measures with clinical indicators of disease severity.

“This exciting research utilizes advanced technology utilized in the bioMUSE study, enhancing beyond traditional MRI techniques in assessing brain volume in MSA patients,” remarked David Stamler, M.D., CEO of Alterity. “Thanks to the ingenuity and technical expertise of our partners at Vanderbilt University Medical Center, we now possess superior instruments for both diagnosing MSA and monitoring brain atrophy over time. Notably, we found that statistically significant reductions in brain volume over twelve months were linked to clinical declines in the disease, reinforcing the value of advanced neuroimaging techniques in evaluating MSA, which have been integrated into our Phase 2 clinical program.”

“While prior MRI research has identified brain volume declines in regions impacted by MSA, consistently monitoring these changes has posed significant challenges. The MSA Atrophy Index enhances our understanding of the condition's progression and supports utilizing brain atrophy metrics to evaluate disease-modifying treatments. These advancements promise a more personalized approach to diagnosis and management of MSA. We are eager to apply this vital technology for patient selection and tracking disease progression in our Phase 3 clinical trials,” Dr. Stamler added.

Offering an objective, quantifiable assessment of brain atrophy in regions commonly affected by MSA, the MSA-AI streamlines the evaluation of disease progression and treatment responses. This technology is especially crucial in MSA, where early diagnosis can be problematic due to symptom overlap with Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). The MSA-AI’s phenotype-independent analysis allows its application to both subtypes of MSA, MSA-P and MSA-C, thereby extending its utility despite varying atrophy patterns. By providing a standardized measure of structural changes, the MSA-AI may enable earlier, more precise diagnoses and improve clinical trial participant selection.

By incorporating a longitudinal cohort from bioMUSE alongside a cross-sectional group of individuals with more advanced MSA, the researchers were able to amass data that represents a wide spectrum of clinical severity and atrophy characteristics. This dual design empowers local and broader assessments of both early-stage and established disease, thereby augmenting the applicability of the findings. MSA patients exhibited significantly lower MSA-AI scores in comparison to all other diagnostic categories, indicating pronounced reductions in brain volumes.

The MSA-AI distinctly differentiated MSA patients from related synucleinopathies, achieving highly significant p-values. Correlations with baseline clinical severity and predictions of disease progression further underscore the MSA-AI's value in clinical settings, demonstrating a comprehensive view of the MSA trajectory. Longitudinal reductions in MSA-AI were also associated with worsening clinical scores over a year, reinforcing its prognostic significance.

Exploring the bioMUSE Study

The bioMUSE initiative is a critical natural history study designed to meticulously trace the trajectory of individuals afflicted with MSA, a condition currently lacking an approved therapeutic solution. Conducted in collaboration with Vanderbilt University Medical Center, the study, under the direction of Daniel Claassen, M.D., M.S., seeks to quantify the progression of MSA using the dense data collected for optimizing Alterity's ongoing randomized ATH434-201 Phase 2 clinical trial.

The bioMUSE study has so far enrolled about 20 individuals displaying clinically probable or established MSA. The insights garnered from this initiative continue to pave the way for identifying crucial biomarkers suitable for evaluating treatment engagement and preliminary efficacy, as well as providing essential clinical insights reflective of MSA progression within patient groups currently participating in the Phase 2 clinical investigation.

Understanding Multiple System Atrophy

Multiple System Atrophy (MSA) is recognized as a rare yet rapidly progressing neurodegenerative disorder linked to the dysfunction of the autonomic nervous system and various motor impairments. Symptoms arise from the gradual degeneration and death of diverse nerve cells within the brain and spinal cord, severely impacting quality of life. MSA presents with a unique combination of movement slowing, rigidity, and autonomic dysfunction, leading to significant challenges in daily living. Additionally, the accumulation of the protein ?-synuclein in glial cells is a pathological hallmark of this condition, with MSA commonly affecting over 15,000 individuals.

At present, while certain symptoms can be managed with medications, there remains a dire lack of treatments capable of slowing disease progression or delivering definitive cures, highlighting the urgent need for ongoing research and innovation in this field.

About Alterity Therapeutics Limited

Alterity Therapeutics, a clinical-stage biotechnology company, is committed to shaping a brighter future for those impacted by neurodegenerative conditions. With a primary focus on developing disease-modifying treatments for Parkinson's disease and associated disorders, Alterity has recently reported encouraging results concerning ATH434 in its Phase 2 trial for MSA. In addition, the company has established a comprehensive drug discovery platform, producing patentable chemical compounds aimed at treating the underlying mechanisms of neurological diseases. Headquartered in Melbourne, Australia, and San Francisco, California, Alterity continues to advance its mission. For more information, consider visiting their official website.

Frequently Asked Questions

What is the MSA Atrophy Index?

The MSA Atrophy Index (MSA-AI) is a novel neuroimaging measure that quantifies brain atrophy in patients with Multiple System Atrophy, providing essential data for tracking disease progression.

How does the MSA-AI improve diagnosis?

The MSA-AI enhances diagnosis by offering an objective measure of brain atrophy that distinguishes MSA from related disorders, thereby facilitating earlier and more accurate identification of the disease.

What is the significance of the bioMUSE study?

The bioMUSE study is crucial as it collects extensive data on MSA progression, aiding in the understanding of clinical characteristics, which ultimately supports the development of targeted therapies.

How does Alterity Therapeutics contribute to MSA treatment?

Alterity Therapeutics focuses on developing innovative, disease-modifying therapies to improve the lives of individuals affected by MSA and related neurodegenerative disorders.

What are the next steps for Alterity Therapeutics?

Alterity aims to leverage the findings from the bioMUSE study and MSA-AI in upcoming clinical trials, enhancing patient outcomes through refined diagnostic and treatment strategies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 90

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 57

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
BET's HBCU Basketball Bet Is Bigger Than Six Games

Updated Category News Views 46

December television usually hands the microphone to the same old basketball machinery, which makes BET putting HBCU hoops in primetime feel overdue rather than merely promotional. Beginning December 3 at 8:00 p.m. ET, BET and Straight Shooter Media will air a six-game series built around Howard University and a rotating slate of opponents. The opener is Grambling State...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Jeff Stern Turns Travel Photography Into a Sensory Memoir

Updated Category News Views 112

Frost in a mountain tent, fermented mare’s milk in a yurt, and coffee in Vietnamese rice paddies are doing more work here than a thousand polished sunset captions ever could. Jeff Stern’s A Change of Scenery, released by Palmetto Publishing on November 17, 2026, comes from a man who spent more than 25 years building brands and then decided the usual labels around...

Continue Reading
Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 118

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 15

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading
Saban Center Partnership Gives Health Learning a Lift

Updated Category News Views 82

A dinosaur race may sound like pure kid bait, but the underlying idea is sturdier than that. Cardiac Solutions and the Seale family are backing an interactive health-and-performance exhibit at Tuscaloosa’s planned Saban Center, a project intended to turn questions about movement, fitness, heart rate and oxygen levels into something children can actually touch, test and...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 108

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading

Top 5 Most Recently Viewed Articles

Kleo Partners with Londis to Revolutionize Retail Convenience

Updated Category News Views 256

Kleo Teams Up with Londis to Improve Convenience Store Operations Kleo, a leading provider of EPOS systems and self-ordering kiosks, is thrilled to announce a new partnership with Londis, one of the premier convenience store chains in the UK. This collaboration marks an important move toward modernizing Londis's operations and enhancing customer experiences through...

Continue Reading
W&T Offshore Sees Production Growth and Impressive Cash Flow

Updated Category News Views 119

W&T Offshore's Third Quarter Performance Highlights W&T Offshore, Inc. (NYSE: WTI) has reported its operational and financial results for the third quarter of 2025. With strong results demonstrating production growth and an impressive cash position, the company declared a dividend of $0.01 per share for the upcoming fourth quarter. Financial Overview The company recorded...

Continue Reading
Examining Sustainability in Grape Seed Extracts Production

Updated Category News Views 172

PLT Health Solutions Unveils Sustainability Report for MegaNatural® Grape Seed Extracts PLT Health Solutions, Inc. has proudly released a comprehensive white paper that delves into the sustainability practices involved in the production of its MegaNatural® grape seed extracts. This insightful document showcases the efforts of California Natural Color, a division of...

Continue Reading
Market Stability Returns as VIX Experiences Significant Drop

Updated Category News Views 126

Understanding the Recent Decline in the VIX The CBOE Volatility Index, commonly known as the VIX, saw a notable decrease of 5%, nearing four-week lows. This decline signifies a shift in market sentiment, reflecting greater stability in investor outlook. The Impact of Political Changes on Volatility With the inauguration of a new U.S. President, the market has reacted...

Continue Reading
AlphaTON Capital Corp. Advances in Cancer Treatment Tokenization

Updated Category News Views 205

AlphaTON Capital Corp. Shares See Significant Gains AlphaTON Capital Corp. (NASDAQ: ATON) has recently garnered attention as its shares experience a notable surge in trading activity. This increase follows the company’s announcement of a non-binding letter of intent to assess the tokenization of single-indication economics for their promising cancer treatment, TT-4,...

Continue Reading